MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Vaginal Versus Combined Use of Progesterone in Fresh IVF/ICSI Cycles

Conditions
Luteal Phase
Interventions
First Posted Date
2021-10-22
Last Posted Date
2021-10-22
Lead Sponsor
University of Athens
Target Recruit Count
698
Registration Number
NCT05089383
Locations
🇬🇷

National and Kapodistrian University of Athens, Athens, Attica, Greece

Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment

Phase 4
Not yet recruiting
Conditions
Fertility Issues
Pregnancy Related
Luteal Phase Defect
Infertility Unexplained
Interventions
First Posted Date
2021-10-15
Last Posted Date
2021-10-15
Lead Sponsor
UMC Utrecht
Target Recruit Count
1008
Registration Number
NCT05080569

Progesterone Action on Endometrium of PCOS

Not Applicable
Completed
Conditions
Polycystic Ovary
Progesterone Resistance
Interventions
First Posted Date
2021-09-30
Last Posted Date
2022-01-20
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
36
Registration Number
NCT05062135

Prediction and Prevention of Twin Premature Birth 2021

Phase 4
Conditions
Preterm Birth
Interventions
First Posted Date
2021-09-29
Last Posted Date
2021-09-29
Lead Sponsor
Caixia Liu
Target Recruit Count
300
Registration Number
NCT05061641
Locations
🇨🇳

caixia Liu, Shenyang, Liaoning, China

Hysteroscopic Findings in Women Using Progesterone Only Pills (Minipills)

Conditions
Women Health
Contraception
Interventions
First Posted Date
2021-08-27
Last Posted Date
2021-08-27
Lead Sponsor
Samuel Gendy
Target Recruit Count
140
Registration Number
NCT05024604
Locations
🇪🇬

Women health hospital , Assuit university, Assiut, Assuit, Egypt

Estradiol and Progesterone Levels Following Frozen Embryo Transfer

Phase 4
Completed
Conditions
Infertility
Interventions
First Posted Date
2021-08-09
Last Posted Date
2025-01-03
Lead Sponsor
Copenhagen University Hospital at Herlev
Target Recruit Count
305
Registration Number
NCT04997525
Locations
🇩🇰

Herlev University Hospital, Herlev, Denmark

A Randomized Controlled Study of Prolonging the Time of Progesterone Supplementation to Improve the Pregnancy Outcome of Single Day 6 Blastocyst Transfer of Freeze-thaw Cycle

Phase 2
Conditions
Infertility
Interventions
First Posted Date
2021-06-24
Last Posted Date
2021-06-24
Lead Sponsor
Nanjing University
Target Recruit Count
900
Registration Number
NCT04938011
Locations
🇨🇳

Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Estradiol and Progesterone in Hospitalized COVID-19 Patients

Phase 2
Terminated
Conditions
Covid19
Interventions
First Posted Date
2021-04-29
Last Posted Date
2023-06-27
Lead Sponsor
Tulane University
Target Recruit Count
10
Registration Number
NCT04865029
Locations
🇺🇸

Tulane University Medical Center, New Orleans, Louisiana, United States

Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle

Not Applicable
Completed
Conditions
Infertility, Female
Interventions
First Posted Date
2021-04-15
Last Posted Date
2021-11-18
Lead Sponsor
Ain Shams University
Target Recruit Count
100
Registration Number
NCT04846218
Locations
🇪🇬

AinShams Maternity Hospital, Cairo, Egypt

Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone

Phase 3
Recruiting
Conditions
IVF
Embryo Loss
Luteal Phase Defect
Interventions
First Posted Date
2021-03-19
Last Posted Date
2024-02-05
Lead Sponsor
University Hospital, Ghent
Target Recruit Count
242
Registration Number
NCT04806919
Locations
🇧🇪

UZ Ghent, Ghent, Belgium

🇧🇪

AZ Delta, Roeselare, Belgium

© Copyright 2025. All Rights Reserved by MedPath